Due to the Corona pandemic, the term “antibody” has become one of the buzzwords of 2020/2021.
The history of antibodies, also known as immunoglobulin, of course reaches back far further than the early months of 2020 – their meaning and importance has not only started gaining relevance with the outbreak of COVID-19.
First groundbreaking results were achieved as early as the 18th century, in the quest to eradicate – or at least successfully contain – smallpox. More currently, antibodies are being studied and drawn upon in the race to find effective vaccines against the Corona virus.
Antibodies are Y-shaped proteins produced by the human body to identify and neutralize foreign objects, more specifically viruses.
The human body’s immune system produces five types of antibodies, each of which has distinct methods of fighting disease and infection by identifying harmful infectious organisms due to their antigens.
While there are “only” five main types of antibodies, each antibody can produce an infinite number of different binding sites that match specific antigens.
In addition, antibodies can be divided into monoclonal and polyclonal types, most of which are artificially manufactured and manipulated to be used in different therapeutics. Just like their natural counterparts they are used to fight certain viruses in the human body.
Antibodies are pivotal in the acquisition of immunity to a disease that a patient has already encountered, a fact that has been known and documented for centuries. Until today, this knowledge forms the basis for extensive research and a medical specialized field commonly known as immunology.
The term itself, which derives from the German “Antikörper”, was first coined in 1891 by Paul Ehrlich, a German Jewish physician and scientist who most notably found a cure against syphilis and who, together with Elie Metchnikoff, was awarded the Nobel Prize in 1908 for their work and insights into immunological defense.
However, it was referenced prior to that, namely in 1890, when Emil von Behring, a German physiologist, and Shibasabura Kitasato, a Japanese physicist, proved that the transfer of serum from animals immunized against diphtheria to animals suffering from it could cure the infected animals.
Today, antibodies are used for a number of applications in various medical and pharmaceutical fields such as research, diagnostics, and therapy. While polyclonal antibodies are made using several immune cells and are widely used in research and diagnostics, monoclonal antibodies are the result of using identical immune cells that are all clones of a specific parent cell.
Due to their ability to target almost any cell surface or secreted molecule with remarkable efficacy and safety, antibodies offer unparalleled opportunities in the development of efficient drugs and therapies targeting a variety of diseases and illnesses.
Recombinant antibodies (rAbs) are monoclonal antibodies that are generated in vitro using synthetic genes. They have a number of advantages in both medical and research applications and are used for the diagnosis of different toxins or pathogens.
In the past decade, several antibodies have been developed for therapeutic applications, primarily targeting tumor, inflammatory or immune diseases such as Crohn’s disease, psoriasis and various types of arthritis.
Afucosylated antibodies on the other hand are engineered monoclonal antibodies with the oligosaccharides in the antibody’s Fc region missing fucose sugar units. This type of antibody increases the antibody-dependent cellular cytotoxicity (ADCC).
ADCC is important regarding the efficacy of cancer antibodies, however, due to nonspecific IgG competing with the drugs for binding to FcγIIIa on natural killer cells, many approved cancer antibodies have less ADCC than could be desired. Afucosylated monoclonal antibodies overcome this problem through improved FcγIIIa binding.
In today’s pharmaceutical and medical sector, antibody production and design plays a crucial role, to increase the activity, extend the half-life, reduce the immunogenicity or increase the functionality of an antibody.
evitria scientists have extensive expertise in antibody design. evitria offers recombinant antibodies, afucosylated antibodies and any other protein for their customers. All projects are completed in a minimum of time and fulfill the highest quality standards in this industry.
One of the most recent additions to evitria’s portfolio is the GlymaxX® technology, licensed from ProBioGen, which facilitates the generation of afucosylated antibodies by means of transient expression in CHO cells.